bioRxiv · 10.1101/2023.12.01.569653
Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Abstract
The emergence of SARS-CoV-2 variants and drug-resistant mutants calls for additional oral antivirals. The SARS-CoV-2 papain-like protease (PLpro) is a promising but challenging drug target. In this study, we designed and synthesized 85 noncovalent PLpro inhibitors that bind to the newly discovered Val70Ub site and the known BL2 groove pocket. Potent compounds inhibited PLpro with inhibitory constant Ki values from 13.2 to 88.2 nM. The co-crystal structures of PLpro with eight leads revealed their interaction modes. The in vivo lead Jun12682 inhibited SARS-CoV-2 and its variants, including nirmatrelvir-resistant strains with EC50 from 0.44 to 2.02 {micro}M. Oral treatment with Jun12682 significantly improved survival and reduced lung viral loads and lesions in a SARS-CoV-2 infection mouse model, suggesting PLpro inhibitors are promising oral SARS-CoV-2 antiviral candidates. One-Sentence SummaryStructure-guided design of SARS-CoV-2 PLpro inhibitors with in vivo antiviral efficacy in a mouse model.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tan, B., Zhang, X., Ansari, A., Jadhav, P., Tan, H., Li, K., Chopra, A., Ford, A., Chi, X., Figueras, F. R., Arnold, E., Deng, X., Wang, J.. 2023-12-03. Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. https://doi.org/10.1101/2023.12.01.569653
Cite the original work for its findings. Save a collection to share your selection of sources.